IFNL1 and infection: Based on all evidence, the uses of IFNLs as drugs against viral infection has been proposed in COVID-19 patients or in individuals at high risk for infection, and current randomized clinical trials are designed with peg-IFNL1 in the case of acute COVID-19 [31].